Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer
Author(s):
Willeumier, J.J.; Hoeven, N.M.A. van der; Bollen, L.; Willems, L.N.A.; Fiocco, M.; Linden, Y.M. van der; Dijkstra, P.D.S.
Published
2017
Publication type
Article / Letter to editor
Date issued
2017-04-30
Language
English
Is part of
Bone and Joint Journal (2017), Vol. 99B, no. 4, p. 516-521
